Semi-Annual Consolidated Statement Of Cash Flows

Kringle Pharma,Inc. - Filing #7264672

Concept 2024-10-01 to
2025-03-31
As at
2025-03-31
As at
2024-09-30
2023-10-01 to
2024-03-31
As at
2024-03-31
As at
2023-09-30
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-511,740,000 JPY
-365,471,000 JPY
Decrease (increase) in trade receivables
JPY
7,560,000 JPY
Decrease (increase) in inventories
44,108,000 JPY
51,000 JPY
Other, net
1,648,000 JPY
22,000 JPY
Subtotal
-403,050,000 JPY
-349,781,000 JPY
Income taxes paid
-1,494,000 JPY
-1,491,000 JPY
Net cash provided by (used in) operating activities
-404,516,000 JPY
-315,253,000 JPY
Cash flows from investing activities
Net cash provided by (used in) investing activities
-155,129,000 JPY
-121,363,000 JPY
Cash flows from financing activities
Net cash provided by (used in) financing activities
1,047,000 JPY
668,409,000 JPY
Net increase (decrease) in cash and cash equivalents
-558,598,000 JPY
231,792,000 JPY
Cash and cash equivalents
1,258,345,000 JPY
1,816,943,000 JPY
1,993,032,000 JPY
1,761,239,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.